New Drug Application submitted to FDA for belumosudil in patients with chronic graft-versus-host disease

Submission for this Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor is supported by data from ROCKstar trial in 132 patients who have received two or more prior lines of systemic therapy, which reported overall response rates of 73% with 200mg/d and 74% with 200mg BD dose.

Source:

Biospace Inc.